Neon Therapeutics Revenue and Competitors

Claim your profile

Boston, MA USA

Location

$161M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Neon Therapeutics's estimated annual revenue is currently $14.1M per year.(i)
  • Neon Therapeutics received $36.0M in venture funding in December 2017.
  • Neon Therapeutics's estimated revenue per employee is $705,250
  • Neon Therapeutics's total funding is $161M.

Employee Data

  • Neon Therapeutics has 20 Employees.(i)
  • 0
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M4-94%N/AN/A
#2
$2.6M17N/AN/AN/A
#3
$6M39-20%$176.5MN/A
#4
$4.5M29N/AN/AN/A
#5
$2.6M17N/AN/AN/A
#6
N/A145-21%$39.5MN/A
#7
N/A0N/A$9.5MN/A
#8
$15.9M159-39%$135MN/A
#9
$1.7M1157%$20.9MN/A
#10
$2.8M1850%$28.9MN/A

Neon Therapeutics is a clinical-stage immuno-oncology company and a leader in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. For more information, please visit www.neontherapeutics.com.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$161M

Total Funding

20

Number of Employees

$14.1M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

Neon Therapeutics News

2022-04-19 - Global Precision Medicine Market Information, Figures and ...

Global Precision Medicine Market Information, Figures and Analytical Insights By 2028 | Neon Therapeutics, Moderna, Inc, Merck & Co., Inc, Bayer AG,...

2022-04-13 - Global Neoantigen Cancer Vaccine Market Report 2022: Focus on ...

Moderna Therapeutics; F. Hoffmann-La Roche Ltd; AstraZeneca plc; Agenus; OSE Immunotherapeutics; Advaxis; Medigene; Neon Therapeutics...

2019-09-08 - Neon Therapeutics up 14% premarket on data supporting MAPTAC technology

Thinly traded nano cap Neon Therapeutics (NASDAQ:NTGN) is up 14% premarket on average volume in response to a just-published paper in ...

2019-09-03 - Analysts Expect Neon Therapeutics (NTGN) Stock to Rise 310%; Rated Strong Buy

Neon Therapeutics Inc (NTGN) stock has fallen -66.87% over the last 12 months, and the average rating from Wall Street analysts is a Strong ...

2019-09-03 - Neon Therapeutics Announces Publication in Immunity of Novel Approach to Predict MHC Class II Cancer-Specific Neoantigens

Neon Therapeutics Announces Publication in Immunity of Novel Approach to Predict MHC Class II Cancer-Specific Neoantigens.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2M20-9%N/A
#2
$3.1M2011%N/A
#3
$2.1M20N/AN/A
#4
$2M20N/AN/A
#5
N/A2011%N/A

Neon Therapeutics Funding

DateAmountRoundLead InvestorsReference
2015-10-02$55.0MAThird Rock VenturesArticle
2017-01-06$70.0MBPartner Fund ManagementArticle
2017-12-06$36.0MBArticle